AR051089A1 - Compuestos de triazoloquinoleina y triazolonaftiridina sustituidas - Google Patents
Compuestos de triazoloquinoleina y triazolonaftiridina sustituidasInfo
- Publication number
- AR051089A1 AR051089A1 ARP050103899A ARP050103899A AR051089A1 AR 051089 A1 AR051089 A1 AR 051089A1 AR P050103899 A ARP050103899 A AR P050103899A AR P050103899 A ARP050103899 A AR P050103899A AR 051089 A1 AR051089 A1 AR 051089A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- carbocyclyl
- heterocyclyl
- alkoxy
- triazolo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Abstract
Composiciones farmacéuticas que los contienen, métodos de preparacion y usos en trastornos asociados con bajos niveles plasmáticos de apo-A1. Reivindicacion 1: Compuesto e triazoloquinoleína o su sal farmacéuticamente aceptable, o su solvato o su profármaco o una combinacion de éstos, caracterizado porque tiene la formula (1) en la que: X representa CH o N; Y representa CH o N; R1 representa H o alquilo C1-2; R2 representa H o alquilo C1-4; R3 representa alquilo C1-6, carbociclilo, carbociclil(alquilo C1-4), heterociclilo o heterociclil(alquilo C1-4), en el que cualquiera de los grupos carbociclilo o heterociclilo está opcionalmente sustituido con uno o dos grupos seleccionados de: halogeno, alquilo C1-6, haloalquilo C1-6, hidroxialquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, nitro, ciano, -COH, -COOH, (alcoxi C1-6)carbonilo, (alquil C1-6)carbonilo, -C(OH)R5R6 (en el que R5 y R6 representan independientemente H o alquilo C1-6), -(CH2)nNR3aR3b y -O(CH2)pNR3aR3b (en el que n representa 1, 2 o 3, p representa 2 o 3, y R3a y R3b representan independientemente H, alquilo C1-6 o carbociclil(alquilo C1-4), o R3a y R3b junto con los átomos interconectores forman un anillo de 5 o 6 miembros, conteniendo dicho anillo opcionalmente uno o dos heteroátomos seleccionados independientemente del grupo que consiste en O, S y N); R4 representa H, hidroxi, halogeno, alquilo C1-6, haloalquilo C1-6, hidroxialquilo C1-6, alquenilo C2-6, alcoxi C1-6, haloalcoxi C1-6, carbociclilo o heterociclilo, en los que el grupo carbociclilo o heterociclilo está opcionalmente sustituido con uno o dos grupos seleccionados de: halogeno, alquilo C1-6, haloalquilo C1-6, alcoxi C1-6, haloalcoxi C1-6, nitro y ciano; con la condicion de que el compuesto no es: 7-cloro-5-fenil[1,2,4]triazolo[4,3-a]quinolin-4-amina; 7-cloro-1-metil-5-fenil[1,2,4]triazolo[4,3-a]quinolin-4-amina; o 7-cloro-5-(2-clorofenil)-1-metil-[1,2,4]triazolo[4,3-a]quinolin-4-amina.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0420970A GB0420970D0 (en) | 2004-09-21 | 2004-09-21 | Novel triazoloquinoline compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR051089A1 true AR051089A1 (es) | 2006-12-20 |
Family
ID=33306953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103899A AR051089A1 (es) | 2004-09-21 | 2005-09-20 | Compuestos de triazoloquinoleina y triazolonaftiridina sustituidas |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR051089A1 (es) |
| GB (1) | GB0420970D0 (es) |
| PE (1) | PE20060818A1 (es) |
| TW (1) | TW200621772A (es) |
| WO (1) | WO2006032470A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006044596A2 (en) | 2004-10-15 | 2006-04-27 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Multi-domain amphipathic helical peptides and methods of their use |
| EP2086975B1 (en) * | 2006-11-20 | 2012-03-14 | Bristol-Myers Squibb Company | 7,8-dihydro-1,6-naphthyridin-5(6h)-ones and related bicyclic compounds as inhibitors of dipeptidyl peptidase iv and methods |
| WO2010049103A1 (en) * | 2008-10-31 | 2010-05-06 | Eth Zurich | Soluble truncated apom proteins and medical uses thereof |
| US8680116B2 (en) | 2009-07-22 | 2014-03-25 | Merck Sharp & Dohme Corp. | Quinolinone PDE2 inhibitors |
| ME02356B (me) | 2009-11-05 | 2016-06-20 | Glaxosmithkline Llc | Inhibitor bromodomena benzodiazepina |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| JP5524343B2 (ja) | 2009-11-05 | 2014-06-18 | グラクソスミスクライン エルエルシー | ベンゾジアゼピンブロモドメイン阻害剤 |
| RU2438672C1 (ru) | 2010-04-30 | 2012-01-10 | Общество с ограниченной ответственностью "Клевер Фарм" | Агент, проявляющий свойства активатора когнитивных функций (варианты) |
| US9085582B2 (en) | 2010-06-22 | 2015-07-21 | Glaxosmithkline Llc | Benzotriazolodiazepine compounds inhibitors of bromodomains |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| EP2838881B1 (en) | 2012-04-20 | 2018-08-08 | AbbVie Inc. | Isoindolone derivatives |
| CN104718201A (zh) | 2012-06-12 | 2015-06-17 | 艾伯维公司 | 吡啶酮和哒嗪酮衍生物 |
| WO2014173241A1 (en) | 2013-04-26 | 2014-10-30 | Beigene, Ltd. | Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones |
| PL3442972T3 (pl) | 2016-04-15 | 2020-07-27 | Abbvie Inc. | Inhibitory bromodomeny |
| WO2021048852A1 (en) | 2019-09-11 | 2021-03-18 | Yeda Research And Development Co. Ltd. | Methods of treating breast cancer |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| US11691971B2 (en) | 2020-06-19 | 2023-07-04 | Incyte Corporation | Naphthyridinone compounds as JAK2 V617F inhibitors |
| MX2023000056A (es) | 2020-07-02 | 2023-04-12 | Incyte Corp | Compuestos tricíclicos de urea como inhibidores de la variante v617f de la cinasa de janus 2 (jak2 v617f). |
| WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| TW202302589A (zh) | 2021-02-25 | 2023-01-16 | 美商英塞特公司 | 作為ｊａｋ２ ｖ６１７ｆ抑制劑之螺環內醯胺 |
| WO2023165528A1 (en) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS50116498A (es) * | 1974-02-27 | 1975-09-11 | ||
| DE60134762D1 (de) * | 2000-10-02 | 2008-08-21 | Janssen Pharmaceutica Nv | Metabotropische glutamatrezeptor-antagonisten |
| GB0108475D0 (en) * | 2001-04-04 | 2001-05-23 | Merck Sharp & Dohme | New compounds |
-
2004
- 2004-09-21 GB GB0420970A patent/GB0420970D0/en not_active Ceased
-
2005
- 2005-09-19 WO PCT/EP2005/010177 patent/WO2006032470A1/en active Application Filing
- 2005-09-19 PE PE2005001075A patent/PE20060818A1/es not_active Application Discontinuation
- 2005-09-19 TW TW094132221A patent/TW200621772A/zh unknown
- 2005-09-20 AR ARP050103899A patent/AR051089A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006032470A1 (en) | 2006-03-30 |
| PE20060818A1 (es) | 2006-08-16 |
| TW200621772A (en) | 2006-07-01 |
| GB0420970D0 (en) | 2004-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR051089A1 (es) | Compuestos de triazoloquinoleina y triazolonaftiridina sustituidas | |
| AR049126A1 (es) | Derivados de 5, 6, 7, 8 - tetrahidroimidazo[1,5a]piridina con actividad inhibitoria de la aldosterona sintasa, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento del hiperaldosterismo y del sindrome de cushing. | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| AR061815A1 (es) | Compuesto de oxo-prolinamida composicion farmaceutica que lo comprende y su uso para la elaboracion de un medicamento | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
| AR044045A1 (es) | Compuesto de piperidincarbonilpiperazina, composicion farmaceutica que lo comprende, su uso para la elaboracion de un medicamento y procedimiento para su preparacion | |
| AR038240A1 (es) | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
| AR020551A2 (es) | Compuestos macrolidos, composiciones y su uso para la preparacion de medicamentos. | |
| AR036093A1 (es) | Compuestos derivados de tiazolidinilo, pirrolidinilo, oxazolidinilo, piperidilo, morfolinilo y tiomorfolinilo, su uso, composiciones farmaceuticas que los comprenden, y compuestos intermediarios | |
| AR028952A1 (es) | Antagonistas receptores de trombina | |
| CU23288B7 (es) | DERIVADOS DE TROPANO ÃsTILES EN TERAPIA | |
| AR050698A1 (es) | Compuesto de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para la preparacion de dicho compuesto | |
| AR063331A1 (es) | Derivados de biaril eter urea y composiciones farmaceuticas | |
| AR082826A2 (es) | Inhibidores heterociclicos de mek, composiciones farmaceuticas que los contienen, usos, y metodos de preparacion de los mismos | |
| AR050433A1 (es) | Derivados piperidilo de quinazolina e isoquinolina | |
| DOP2006000193A (es) | Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso | |
| RS52853B (en) | SPIRO SUBSTITUTED COMPOUNDS AS ANGIOGENESIS INHIBITORS | |
| AR067060A1 (es) | Derivados de guanina policiclicos y sus metodos de uso | |
| CY1110261T1 (el) | Παραγωγα της κουμαρινης που χρησιμοποιουνται σαν αντιπηκτικα | |
| ECSP067111A (es) | Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica | |
| CO4950553A1 (es) | Compuestos de 7-tetrahidroisoquinolinas y procedimiento para su preparacion | |
| AR041992A1 (es) | Compuesto de piridinil benzoheterociclico, composicion farmaceutica que lo comprende y su uso para prepararla | |
| DK1475379T3 (da) | Anvendelse af scopinesterderivater til fremstilling af lægemidler | |
| PA8607701A1 (es) | Compuestos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |